<DOC>
	<DOCNO>NCT02990611</DOCNO>
	<brief_summary>Real-Life Efficacy Safety Nivolumab monotherapy combination Ipilimumab Patients Advanced ( Unresectable Metastatic ) Melanoma</brief_summary>
	<brief_title>Real-Life Efficacy Safety Nivolumab Monotherapy Combination With Ipilimumab Patients With Advanced ( Unresectable Metastatic ) Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>â‰¥ 18 year advance melanoma ( Stage III/Stage IV ) histologically confirm diagnosis treatment decision nivolumab mono combination therapy already take sign informed consent current primary diagnosis cancer advance melanoma , require systemic treatment previous treatment nivolumab current active participation interventional clinical trial treatment advance melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>